Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis

Figure 3 Liver smooth muscle actin content. A: Immunohistochemistry of liver tissue for SMA content from control (Con), fibrotic (CCl₄), rosiglitazone (Rosi), serelaxin (Rln) or combination-treated (Rosi+Rln) mice. Bar: 100 μm; B: SMA staining quantified. Data are expressed as mean ± SE, and analyzed by ANOVA (n = 5). ^aP < 0.001 vs Con; ^bP < 0.05 vs CCl₄; ^cP < 0.05 vs CCl₄, Rosi, or Rln.